Genentech, Incyte Pharmaceuticals Inc. deal

Under a revised agreement, the rights cover all Incyte and GNE technology related to BPI, which is being developed to treat sepsis. GNE will increase its 10 percent equity stake in Incyte by an undetermined amount in Incyte's next round of financing and will receive a royalty on BPI sales.

Incyte was able to revise the 1991 agreement after GNE failed to meet all of its development obligations, said Roy Whitfield, president of the privately held company. GNE had responsibility for clinical development in exchange for exclusive marketing rights in the U.S. and Europe. ...